AAV gene therapy for GBA1-related diseases.
AAV gene therapy for GBA1-related diseases.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Waltham, US · Author affiliation
Genomic Medicine Unit, Sanofi, Waltham, MA 02451, USA.Location evidence
Cambridge, US · Author affiliation
Translational Medicine Unit, Sanofi, Cambridge, MA 02141, USA.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Mutations in GBA1, the gene encoding glucocerebrosidase (GCase), are the most common risk factor for Parkinson's disease (PD). GBA-PD patients are a genetic subpopulation of PD carrying heterozygous mutations in GBA1. Additionally, bi-allelic mutations in GBA1 cause Gaucher disease (GD), a lysosomal storage disorder. Loss of GCase activity, a lysosomal enzyme, leads to the accumulation of lipid substrates, disrupting lipid homeostasis and causing lysosomal dysfunction. Here, we report an AAV-mediated GBA1 replacement strategy to treat diseases arising from mutations in GBA1. We engineered human GCase to be readily secretable to facilitate broad cross-correction. We developed CBE (conduritol β-epoxide)-induced lipid accumulation models to assess efficacy in mice and non-human primates (NHPs). Based on data across species, we nominated AAV.GMU01 SS3-GBA1 as our lead candidate. SS3-GBA1 is robustly secreted, cross-corrects across tissues and promotes lipid clearance. By comparing human GCase levels in AAV-treated NHP brains to healthy human donor brains, we demonstrate that AAV.GMU01 SS3-GBA1 replenishes the GCase deficit seen in GBA-PD patients, thus restoring GCase to near-physiological levels. Importantly, AAV.GMU01 SS3-GBA1 is well tolerated with no adverse findings. Collectively, we establish a therapeutic strategy for the treatment of GD and GBA-associated PD with a single-gene therapy product.